Engineered T cells controlled by granulocyte colony-stimulating factor eradicate murine melanoma without lymphodepletion or interleukin-2
Sam C Preshaw, Megan Fuller, Cameron J. Powell, Katy Milne, Kassandra Sewell, Mitchell Brady Adamson, Alexi S. Pearson-Lund, Marco Joly, Sydney Goodwin, Niloufar Shakerian, Natalie J.S. Taylor, Ming Zi Xu, Danielle Klassen, Taise Bryce, Julian C Smazynski, , Brad H. Nelson
This study engineers T cells to respond to G-CSF instead of IL-2, enabling effective melanoma treatment without lymphodepletion or IL-2.
bioRxiv · Oct 28, 2026 · PreprintImmunology